Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Zonagen (zona) - good buy? -- Ignore unavailable to you. Want to Upgrade?

To: Linda Kaplan who wrote (6264)	3/18/1999 8:46:00 AM
From: Craig Markell	Read Replies (1) \| Respond to of 7041

Looks like SGP wants Zonagen to unload the small potatoes (non core) business before they buy Zonagen later in the year.

To: Linda Kaplan who wrote (6264)	3/18/1999 9:10:00 AM
From: Linda Kaplan	Respond to of 7041

MUSE Receives Marketing Licenses in France, Norway, Austria and Portugal; Astra AB to Pay $2 Million Milestone MOUNTAIN VIEW, Calif.--(BW HealthWire)--March 18, 1999--VIVUS, Inc. (Nasdaq:VVUS) today announced that the Company has received notification that the marketing license for MUSE(R) (alprostadil) in France has been granted. This license triggers a $2 million milestone payment to VIVUS from ASTRA. In addition, Norway and the European Union countries of Portugal and Austria have recently issued licenses for MUSE. Founded in 1991, VIVUS, Inc. is a leader in the development of advanced therapeutic systems for the treatment of erectile dysfunction, commonly referred to as impotence. VIVUS has pioneered a novel therapy for erectile dysfunction known as the transurethral system for erection. This therapy consists of a proprietary, non-invasive drug delivery system that delivers pharmacologic agents via the urethra. Note to editors and investors: Additional written materials, recent releases and Company information are available through a variety of sources, including the VIVUS home page (www.vivus.com) and the VIVUS Fax-On-Demand Service (1-888-329-5719). CONTACT: VIVUS, Inc., Mountain View Nina W. Ferrari, 650/934-5200 IR@VIVUS.com To edit your profile, go to keyword NewsProfiles. For all of today's news, go to keyword News.